{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:58:21Z","timestamp":1785859101373,"version":"3.56.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1097\/mou.0b013e3283523ba0","type":"journal-article","created":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T13:30:33Z","timestamp":1332509433000},"page":"175-182","source":"Crossref","is-referenced-by-count":5,"title":["Novel agents for the management of castration-resistant prostate cancer"],"prefix":"10.1097","volume":"22","author":[{"given":"Housam","family":"Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210206","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/bjc.1989.385","article-title":"A novel hybridoma antibody (PASE4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry.","volume":"60","author":"Haines","year":"1989","journal-title":"Br J Cancer"},{"key":"R2-3-20210206","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1309\/G6PR-Y774-X738-FG2K","article-title":"Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores.","volume":"117","author":"Goldstein","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"R3-3-20210206","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/pros.20040","article-title":"Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial.","volume":"60","author":"Burch","year":"2004","journal-title":"Prostate"},{"key":"R4-3-20210206","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.","volume":"24","author":"Small","year":"2006","journal-title":"J Clin Oncol"},{"key":"R5-3-20210206","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.","volume":"115","author":"Higano","year":"2009","journal-title":"Cancer"},{"key":"R6-3-20210206","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2002.11.021","article-title":"Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration.","volume":"20","author":"Smaletz","year":"2002","journal-title":"J Clin Oncol"},{"key":"R7-3-20210206","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2003.06.100","article-title":"Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.","volume":"21","author":"Halabi","year":"2003","journal-title":"J Clin Oncol"},{"key":"R8-3-20210206","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"for the IMPACT Study InvestigatorsSipuleucel-T immunotherapy for castration-resistant prostate cancer.","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"R9-3-20210206","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.coph.2008.07.005","article-title":"Targeting the androgen receptor pathway in prostate cancer.","volume":"8","author":"Chen","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"R10-3-20210206","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/jcb.10653","article-title":"Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.","volume":"91","author":"Taplin","year":"2004","journal-title":"J Cell Biochem"},{"key":"R11-3-20210206","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0960-0760(02)00064-X","article-title":"Transition to androgen-independence in prostate cancer.","volume":"81","author":"Navarro","year":"2002","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R12-3-20210206","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","article-title":"Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.","volume":"23","author":"Scher","year":"2005","journal-title":"J Clin Oncol"},{"key":"R13-3-20210206","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/35094009","article-title":"The development of androgen independent prostate cancer.","volume":"1","author":"Feldman","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"R14-3-20210206","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/jnci\/93.22.1687","article-title":"Androgen receptor signaling in androgen-refractory prostate cancer.","volume":"93","author":"Grossmann","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"R15-3-20210206","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1677\/erc.1.00525","article-title":"Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.","volume":"11","author":"Scher","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"R16-3-20210206","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-2004-861547","article-title":"Adrenal androgens and intracrinology.","volume":"22","author":"Labrie","year":"2004","journal-title":"Semin Reprod Med"},{"key":"R17-3-20210206","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/1078-0432.CCR-1146-03","article-title":"The androgen axis in recurrent prostate cancer.","volume":"10","author":"Mohler","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R18-3-20210206","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1677\/joe.0.0600117","article-title":"Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro.","volume":"60","author":"Harper","year":"1974","journal-title":"J Endocrinol"},{"key":"R19-3-20210206","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/01485010151094010","article-title":"Adrenal steroids in human prostatic cancer cell lines.","volume":"46","author":"Koh","year":"2001","journal-title":"Arch Androl"},{"key":"R20-3-20210206","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/jnci\/86.3.222","article-title":"Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of hormone-refractory prostate cancer.","volume":"86","author":"Sartor","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"R21-3-20210206","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1755::AID-CNCR9>3.0.CO;2-D","article-title":"Simultaneous and antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.","volume":"80","author":"Small","year":"1997","journal-title":"Cancer"},{"key":"R22-3-20210206","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0022-5347(01)64924-3","article-title":"Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.","volume":"157","author":"Small","year":"1997","journal-title":"J Urol"},{"key":"R23-3-20210206","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0022-5347(05)64675-7","article-title":"Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.","volume":"168","author":"Harris","year":"2002","journal-title":"J Urol"},{"key":"R24-3-20210206","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/01.ju.0000147013.09157.8e","article-title":"A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.","volume":"173","author":"Figg","year":"2005","journal-title":"J Urol"},{"key":"R25-3-20210206","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2004.06.037","article-title":"Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).","volume":"22","author":"Small","year":"2004","journal-title":"J Clin Oncol"},{"key":"R27-3-20210206","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","article-title":"Hormonal impact of the -hydroxylaseC(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer.","volume":"90","author":"ODonnell","year":"2004","journal-title":"Br J Cancer"},{"key":"R28-3-20210206","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"key":"R29-3-20210206","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2009.24.6819","article-title":"Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.","volume":"28","author":"Reid","year":"2010","journal-title":"J Clin Oncol"},{"key":"R30-3-20210206","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer.","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"R31-3-20210206","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistance prostate cancer: a Canadian randomized trial with palliative end points.","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"R32-3-20210206","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","article-title":"Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: results from the cancer and leukemia group B 9182 study.","volume":"17","author":"Kantoff","year":"1999","journal-title":"J Clin Oncol"},{"key":"R34-3-20210206","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1200\/JCO.2008.20.1228","article-title":"Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.","volume":"27","author":"Sternberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"R35-3-20210206","first-page":"303","article-title":"In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines abstract 1923.","volume":"41","author":"Aller","year":"2000","journal-title":"Proc Am Assoc Cancer Res"},{"key":"R36-3-20210206","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.patbio.2005.03.003","article-title":"Update on tubulin binding agents.","volume":"54","author":"Attard","year":"2006","journal-title":"Pathol Biol (Paris)"},{"key":"R37-3-20210206","first-page":"214","article-title":"Preclinical evaluation of TXD258, a new taxoid abstract 1364.","volume":"41","author":"Bissery","year":"2000","journal-title":"Proc Am Assoc Cancer Res"},{"key":"R38-3-20210206","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/1078-0432.CCR-08-0596","article-title":"Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-h infusion every 3 weeks in patients with advanced solid tumors.","volume":"15","author":"Mita","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R39-3-20210206","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdn171","article-title":"A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients.","volume":"19","author":"Pivot","year":"2008","journal-title":"Ann Oncol"},{"key":"R40-3-20210206","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"R42-3-20210206","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","article-title":"Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs.","volume":"87","author":"Mittan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R43-3-20210206","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer.","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"R44-3-20210206","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer.","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"R45-3-20210206","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","article-title":"Assessment of fracture risk.","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"R46-3-20210206","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"R47-3-20210206","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist induced bone loss in men with prostate cancer.","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol"},{"key":"R48-3-20210206","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer.","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"R49-3-20210206","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"R50-3-20210206","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"}],"container-title":["Current Opinion in Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001665-201203000-00085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:05:36Z","timestamp":1785855936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00042307-201205000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mou.0b013e3283523ba0","relation":{},"ISSN":["0963-0643"],"issn-type":[{"value":"0963-0643","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}